Literature DB >> 24950733

Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.

Hanno Niess1, Peter Camaj, Andrea Renner, Ivan Ischenko, Yue Zhao, Stefan Krebs, Josef Mysliwietz, Carsten Jäckel, Peter J Nelson, Helmut Blum, Karl-Walter Jauch, Joachim W Ellwart, Christiane J Bruns.   

Abstract

Cancer stem cells (CSCs) have been proposed to underlie the initiation and maintenance of tumor growth and the development of chemoresistance in solid tumors. The identification and role of these important cells in pancreatic cancer remains controversial. Here, we isolate side population (SP) cells from the highly aggressive and metastatic human pancreatic cancer cell line L3.6pl and evaluate their potential role as models for CSCs. SP cells were isolated following Hoechst 33342 staining of L3.6pl cells. SP, non-SP, and unsorted L3.6pl cells were orthotopically xenografted into the pancreas of nude mice and tumor growth observed. RNA was analyzed by whole genome array and pathway mapping was performed. Drug resistant variants of L3.6pl were developed and examined for SP proportions and evaluated for surface expression of known CSC markers. A distinct SP with the ability to self-renew and differentiate into non-SP cells was isolated from L3.6pl (0.9 % ± 0.22). SP cells showed highly tumorigenic and metastatic characteristics after orthotopic injection. Transcriptomic analysis identified modulation of gene networks linked to tumorigenesis, differentiation, and metastasization in SP cells relative to non-SP cells. Wnt, NOTCH, and EGFR signaling pathways associated with tumor stem cells were altered in SP cells. When cultured with increasing concentrations of gemcitabine, the proportion of SP cells, ABCG2(+), and CD24(+) cells were significantly enriched, whereas 5-fluorouracil (5-FU) treatment lowered the percentage of SP cells. SP cells were distinct from cells positive for previously postulated pancreatic CSC markers. The Hoechst-induced side population in L3.6pl cells comprises a subset of tumor cells displaying aggressive growth and metastasization, increased gemcitabine-, but not 5-FU resistance. The cells may act as a partial model for CSC biology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24950733     DOI: 10.1007/s11523-014-0323-z

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.493


  54 in total

Review 1.  Applying the principles of stem-cell biology to cancer.

Authors:  Ricardo Pardal; Michael F Clarke; Sean J Morrison
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

2.  A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.

Authors:  G G Wulf; R Y Wang; I Kuehnle; D Weidner; F Marini; M K Brenner; M Andreeff; M A Goodell
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

Review 3.  MicroRNAs, cancer and cancer stem cells.

Authors:  Amy L Zimmerman; Shiyong Wu
Journal:  Cancer Lett       Date:  2010-10-20       Impact factor: 8.679

4.  Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): implications for antitumoral activity.

Authors:  Beatriz Díez-Dacal; Javier Gayarre; Severine Gharbi; John F Timms; Claire Coderch; Federico Gago; Dolores Pérez-Sala
Journal:  Cancer Res       Date:  2011-04-20       Impact factor: 12.701

5.  Characterization of a side population of cancer cells from human gastrointestinal system.

Authors:  Naotsugu Haraguchi; Tohru Utsunomiya; Hiroshi Inoue; Fumiaki Tanaka; Koshi Mimori; Graham F Barnard; Masaki Mori
Journal:  Stem Cells       Date:  2005-10-20       Impact factor: 6.277

Review 6.  Stem cells and solid cancers.

Authors:  Stuart A C McDonald; Trevor A Graham; Stefanie Schier; Nicholas A Wright; Malcolm R Alison
Journal:  Virchows Arch       Date:  2009-06-05       Impact factor: 4.064

7.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.

Authors:  Shuomin Zhu; Hailong Wu; Fangting Wu; Daotai Nie; Shijie Sheng; Yin-Yuan Mo
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617

9.  Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma.

Authors:  Jong-Kook Park; Eun Joo Lee; Christine Esau; Thomas D Schmittgen
Journal:  Pancreas       Date:  2009-10       Impact factor: 3.327

10.  Persistence of side population cells with high drug efflux capacity in pancreatic cancer.

Authors:  Jing Zhou; Chun-You Wang; Tao Liu; Bin Wu; Feng Zhou; Jiong-Xin Xiong; He-Shui Wu; Jing Tao; Gang Zhao; Ming Yang; Shan-Miao Gou
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

View more
  23 in total

1.  Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer.

Authors:  Yue Zhao; Lu Zhao; Ivan Ischenko; Qi Bao; Bettina Schwarz; Hanno Nieß; Yan Wang; Andrea Renner; Josef Mysliwietz; Karl-Walter Jauch; Peter J Nelson; Joachim W Ellwart; Christiane J Bruns; Peter Camaj
Journal:  Target Oncol       Date:  2015-02-03       Impact factor: 4.493

2.  Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.

Authors:  Yue Zhao; Annelore Altendorf-Hofmann; Ioannis Pozios; Peter Camaj; Therese Däberitz; Xiaoyan Wang; Hanno Niess; Hendrik Seeliger; Felix Popp; Christopher Betzler; Utz Settmacher; Karl-Walter Jauch; Christiane Bruns; Thomas Knösel
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-17       Impact factor: 4.553

3.  Targeting BCRP/ABCG2 by RNA interference enhances the chemotherapy sensitivity of human colon cancer side population cells.

Authors:  Jun Hu; Jian Li; Xin Yue; Jia-Cang Wang; Jun-Feng Wang; Jian-Zhong Liu; Da-Lu Kong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-04-11

4.  Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells.

Authors:  Deepanshi Dhar; Gagan Deep; Sushil Kumar; Michael F Wempe; Komal Raina; Chapla Agarwal; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2018-05-18       Impact factor: 4.784

5.  A miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer.

Authors:  Alakesh Bera; Kolaparthi VenkataSubbaRao; Muthu Saravanan Manoharan; Ping Hill; James W Freeman
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

Review 6.  In vitro models of cancer stem cells and clinical applications.

Authors:  Sara S Franco; Karolina Szczesna; Maria S Iliou; Mohammed Al-Qahtani; Ali Mobasheri; Julianna Kobolák; András Dinnyés
Journal:  BMC Cancer       Date:  2016-09-30       Impact factor: 4.430

7.  Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells.

Authors:  Yuran Gao; Zhicheng Zhang; Kai Li; Liying Gong; Qingzhu Yang; Xuemei Huang; Chengcheng Hong; Mingfeng Ding; Huanjie Yang
Journal:  Cell Death Dis       Date:  2017-07-13       Impact factor: 8.469

Review 8.  Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer.

Authors:  Jiangang Zhao; Jiahui Li; Hans A Schlößer; Felix Popp; Marie Christine Popp; Hakan Alakus; Karl-Walter Jauch; Christiane J Bruns; Yue Zhao
Journal:  Stem Cells Int       Date:  2017-08-06       Impact factor: 5.443

9.  Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.

Authors:  Rama Krishna Nimmakayala; Frank Leon; Satyanarayana Rachagani; Sanchita Rauth; Palanisamy Nallasamy; Saravanakumar Marimuthu; Gautam K Shailendra; Yashpal S Chhonker; Seema Chugh; Ramakanth Chirravuri; Rohitesh Gupta; Kavita Mallya; Dipakkumar R Prajapati; Subodh M Lele; Thomas C Caffrey; Jean L Grem; Paul M Grandgenett; Michael A Hollingsworth; Daryl J Murry; Surinder K Batra; Moorthy P Ponnusamy
Journal:  Oncogene       Date:  2020-10-27       Impact factor: 8.756

10.  PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions.

Authors:  Rama Krishna Nimmakayala; Sanchita Rauth; Ramakanth Chirravuri Venkata; Saravanakumar Marimuthu; Palanisamy Nallasamy; Raghupathy Vengoji; Subodh M Lele; Satyanarayana Rachagani; Kavita Mallya; Mokenge P Malafa; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.